Federica Marmorino
Pisa, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years.
Journal: ESMO open
Published: February 02, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2026
The Impact of Surgical Resection in Early Onset Colorectal Cancer Patients With Liver Limited Disease.
Journal: Clinical colorectal cancer
Published: November 24, 2025
Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement Study.
Journal: Clinical colorectal cancer
Published: October 17, 2025
Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm.
Journal: The oncologist
Published: October 02, 2025
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?
Journal: JCO precision oncology
Published: September 10, 2025
Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy.
Journal: Cancer cell
Published: September 01, 2025
A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer.
Journal: Scientific reports
Published: August 14, 2025
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients.
Journal: ESMO open
Published: June 18, 2025
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers.
Journal: Oncoimmunology
Published: April 07, 2025
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 25, 2025
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.
Journal: Nature communications
Published: November 11, 2024
Last Updated: 09/26/2026